Sleep disruption fuels Alzheimer risk via apnea, fragmentation, and inflammation; improving consolidated sleep, medication review, and sleep-specialist teamwork may protect cognition.
|Videos|June 10, 2021
Ushering in the Golden Era of Alzheimer Drug Development?
Author(s)RJ Tesi, MD
What effect will aducanumab have on Alzheimer disease treatment?
Advertisement
RJ Tesi, MD, discusses the recent aducanumab FDA approval and the implications it will have on the treatment of Alzheimer disease.
Dr Tesi is CEO and Chief Medical Officer of
Advertisement
Related to this article
UK AD-SMART platform trial speeds Alzheimer disease treatment discovery by testing multiple repurposed drugs at once across NHS sites, aiming to protect memory and quality of life.
Neurocrine launches a phase 2 trial of once-daily NBI-'567, testing a selective muscarinic agonist to boost cognition in mild to moderate Alzheimer disease.
Advertisement
Advertisement
Trending on Psychiatric Times
1
When Antidepressants Stop Working: Understanding Tachyphylaxis in Clinical Practice
2
Sleep Disruption and Alzheimer Disease: A Bidirectional, Treatable Relationship
3
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
4
FDA Aligns on Key Elements of Phase 3 Study of Zervimesine for Dementia With Lewy Bodies
5